Ozempic vs Wegovy: same molecule, different label

The two products differ in their FDA-approved indication, their dose ceiling, and almost everything downstream of those two facts.

Ozempic is FDA-approved for type 2 diabetes, with the goal of improving glycemic control, plus a cardiovascular risk-reduction indication for patients with type 2 diabetes and known heart disease. Its dose schedule starts at 0.25 mg weekly, titrates up through 0.5 mg, 1.0 mg, and 2.0 mg over months, with 2.0 mg as the typical maximum.

Wegovy is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. It is also approved for adolescents 12 and older meeting comparable weight criteria, and for cardiovascular risk reduction in adults with established heart disease and obesity. Its titration ends at 2.4 mg weekly, slightly higher than Ozempic.

Because the indications differ, insurance behaves differently for each. Ozempic is typically covered by most plans for type 2 diabetes; Wegovy coverage for weight management is patchy, plan-dependent, and often requires prior authorization, BMI documentation, or step therapy. List prices for both run high in the United States, in the rough neighborhood of $1,000 to $1,400 per month as of writing, before any rebate or coupon.

The pen design is similar but not interchangeable. Ozempic pens deliver 0.25, 0.5, 1.0, or 2.0 mg depending on the strength prescribed; Wegovy pens are dose-specific and shipped at the strength your prescription calls for. You cannot use an Ozempic pen to deliver a Wegovy 2.4 mg dose, and the cartridge volumes differ.

A common pattern: a clinician prescribes Ozempic to a patient without type 2 diabetes for weight loss. This is off-label use, which is legal but not what the FDA cleared the drug for. Off-label prescribing is common across medicine and is a clinical judgment call by the prescriber, not an automatic green flag.

What people should understand: insurance plans almost always require an on-label diagnosis to cover Ozempic, so off-label prescriptions are usually paid out of pocket or through a manufacturer savings card if eligibility allows. Off-label use also caps the dose at the Ozempic maximum of 2.0 mg per week, which is below Wegovy's 2.4 mg, and weight outcomes in trials track the dose. If long-term weight management is the goal, an on-label Wegovy prescription is generally the cleaner path when insurance and clinical fit allow.

The right move is to ask your prescriber whether your situation actually fits Wegovy's indications. If it does, switching to Wegovy avoids the off-label gray area and unlocks the higher dose ceiling. If it does not, your prescriber can explain the trade-offs.

Switching from Ozempic to Wegovy or back is reasonable and common, especially when insurance coverage changes or the clinical indication shifts. Because the molecule is the same, the switch is conceptually simple: same drug, different label and different dose ceiling.

In practice, switches are not a clean dose conversion. Ozempic 1.0 mg is not exactly equivalent to Wegovy 1.0 mg in clinical impact, partly because the titration rhythm and the maximum dose differ. Most prescribers handle a switch by re-titrating from a step that closely matches the patient's current dose, then adjusting up if tolerated. A patient stable on Ozempic 2.0 mg often moves to Wegovy 2.4 mg, but not always immediately.

Do not switch on your own. Each pen is dose-specific, the prescription is written for that dose, and an unsupervised switch can drive nausea or other side effects without warning. This is a conversation for your prescriber.

Side effects are broadly the same across both products because the molecule is the same. The most common ones are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and reflux. These are typically worst during titration and during the first week or two after each dose increase, then settle.

Less common but more serious side effects are listed identically on both labels: pancreatitis, gallbladder disease, kidney injury usually tied to dehydration from heavy nausea, and rare allergic reactions. Both labels carry the boxed warning about thyroid C-cell tumors based on rodent studies, and both contraindicate use in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Weight loss outcomes in clinical trials are dose-dependent. In published trials of semaglutide for weight management, average weight loss at 2.4 mg weekly is meaningfully higher than at 1.0 or 2.0 mg. That is the main practical reason Wegovy at 2.4 mg tends to edge out Ozempic at 2.0 mg for pure weight outcomes. For type 2 diabetes glycemic control, both work; the gap there is smaller and the indication question dominates the choice.

Both Ozempic and Wegovy are expensive in the United States without insurance, with U.S. list prices generally in the rough range of $1,000 to $1,400 per month as of writing. Real out-of-pocket costs vary widely depending on plan coverage, manufacturer savings cards, eligibility for patient assistance programs, and whether the prescription is on-label.

Novo Nordisk runs savings programs for both: an Ozempic savings card for commercially insured patients with a covered diabetes prescription, and a Wegovy savings program for commercially insured patients whose plan covers Wegovy. Government insurance plans, including Medicare and Medicaid, are generally excluded from these savings cards.

Compounded semaglutide became widely available during the FDA shortage period and is sometimes priced lower than branded products. The FDA shortage status of semaglutide has changed; as of writing, large-scale compounding under the shortage exemption is no longer broadly permitted, and compounding pharmacies have been rolling back availability accordingly. If you are considering a compounded option, confirm the pharmacy's current legal basis with your prescriber before refilling.

This is general information, not pricing advice. Talk to your pharmacist for the actual cost on your plan.

Both Ozempic and Wegovy live as semaglutide in Phaze, with the same dose cycle logic, the same titration schedule support, and the same lab integration. Whether your pen is labeled Ozempic 1.0 mg or Wegovy 1.7 mg, the underlying tracking is the same: weekly dose, injection site rotation, side effect log, and the trend lines that matter.

The Lab Tracker covers 40+ biomarkers with your dose overlaid, so an A1C drop after a step-up to 2.0 mg or 2.4 mg is visible in one chart. The GLP-1 lab tracking guide covers what to test and when. Compare features on the comparison page, or read the medication-specific pages for Ozempic, Wegovy, and semaglutide for more detail.

The choice between Ozempic and Wegovy belongs in the conversation with your prescribing clinician. Three concrete questions:

1. "Given my BMI, comorbidities, and goals, which on-label option fits me?" An on-label prescription is almost always cleaner for insurance and dose flexibility.

2. "What is the dose plan, and what is the target maximum?" Knowing whether you are aiming for 2.0 mg on Ozempic or 2.4 mg on Wegovy frames the rest of the year.

3. "If insurance changes or coverage drops, what is the backup plan?" Coverage shifts are common; a written plan beats a scramble at the pharmacy counter.

This guide is general information, not medical advice and not a recommendation to switch. Your prescriber knows your full picture.